Clinical Trials Browser

Terminated × OTHER × amrubicin × Clear all

NCT01331824 2018-04-23

Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

Phase 2 Terminated

22 enrolled 12 charts

Urinary Bladder Neoplasms, Neoplasm Metastasis